New York-based ProofPilot, a frontrunner in the Clinical Experience Platform (CXP) space, has announced the successful closing of its Series C funding round. Sopris Capital led the investment, with participation from Mitsui & Co. (U.S.A.), Inc.
This significant investment underscores the growing recognition of ProofPilot’s innovative approach to clinical trials. While advancements in data capture and AI have dominated recent headlines, ProofPilot shines a light on a crucial but often overlooked aspect: the overall experience for participants, sponsors, and research sites.
Revolutionizing the Clinical Trial Landscape
“Our focus is on humanizing the clinical trial experience,” declared Chris Venezia, CEO of ProofPilot. “By prioritizing clear communication and collaboration between all stakeholders, we aim to streamline the process and ultimately accelerate the development of life-saving therapies.”
ProofPilot’s user-friendly platform, StudyCoPilot, acts as a central hub, fostering seamless communication and collaboration between sponsors, patients, and research sites throughout the entire clinical trial journey. This holistic approach tackles key challenges within the industry, including improving diversity, equity, and inclusion (DE&I) efforts, streamlining participant recruitment and retention, and minimizing administrative burdens on research sites.
Proven Success and Continued Growth
ProofPilot’s capabilities have been successfully scaled to meet the demands of large-scale clinical trials. The company boasts a prestigious clientele, with leading pharmaceutical companies around the world deploying StudyCoPilot.
“We are thrilled to partner with ProofPilot and contribute to their continued success,” commented Abinav Sankar, Partner at Sopris Capital. “The potential of this technology is undeniable, and we have immense faith in the ProofPilot team.”
A Brighter Future for Clinical Research
ProofPilot’s innovative platform represents a significant leap forward in the world of clinical trials. By prioritizing the experience of all stakeholders, ProofPilot paves the way for a more efficient, inclusive, and ultimately more successful clinical research environment. This investment will undoubtedly fuel ProofPilot’s continued growth and empower them to make a lasting impact on the development of life-changing medical treatments.
If you need further assistance or have any corrections, please reach out to editor@thetimesmag.com.
